We recently celebrated the AI-based analysis of ten million tests performed by over 20,000 patients with ForeseeHome. The device is part of a comprehensive remote monitoring service for intermediate age-related macular degeneration (AMD) patients at risk of developing the sight threatening wet form of the disease. The service monitors patients between office eye exams, when it’s difficult to manage the acute onset of wet disease that requires timely treatment.
“Patients require ongoing assistance and a positive and empowering experience to be successful across years of home diagnostic testing. Their home monitoring experience reflects positively on physicians and their practice in addition to the medical benefit”, said Barbara Benedict, Vice President of Notal Vision Monitoring Center Strategy and Operations. “Directed by practicing ophthalmologists and supported by a team of certified ophthalmic professionals, the Monitoring Center is a Medicare accredited and HIPAA compliant digital healthcare provider and the epicenter of patient and physician engagement that provides a safety net against vision loss between eye exams.”
“The real-word data published last year shows that the performance of the ForeseeHome program resembles the findings from the randomized controlled AREDS2-HOME study, which ultimately led to Medicare coverage of the monitoring service we provide,” said Kester Nahen, PhD, CEO of Notal Vision.
This impressive milestone demonstrates the Notal Vision Monitoring Center’s unwavering commitment to AMD patient care. We look forward to celebrating the next 10 million tests.
